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35 Cl dynamic nuclear polarization solid-state NMR of active
pharmaceutical ingredients
Abstract
In this work, we show how to obtain eﬃcient dynamic nuclear polarization (DNP) enhanced 35Cl solid-state
NMR (SSNMR) spectra at 9.4 T and demonstrate how they can be used to characterize the molecular-level
structure of hydrochloride salts of active pharmaceutical ingredients (APIs) in both bulk and low wt% API
dosage forms. 35Cl SSNMR central-transition powder patterns of chloride ions are typically tens to hundreds
of kHz in breadth, and most cannot be excited uniformly with high-power rectangular pulses or acquired
under conditions of magic-angle spinning (MAS). Herein, we demonstrate the combination of DNP and
1H–35Cl broadband adiabatic inversion cross polarization (BRAIN-CP) experiments for the acquisition of
high quality wideline spectra of APIs under static sample conditions, and obtain signals up to 50 times greater
than in spectra acquired without the use of DNP at 100 K. We report a new protocol, called spinning-on
spinning-off (SOSO) acquisition, where MAS is applied during part of the polarization delay to increase the
DNP enhancements and then the MAS rotation is stopped so that a wideline 35Cl NMR powder pattern free
from the effects of spinning sidebands can be acquired under static conditions. This method provides an
additional two-fold signal enhancement compared to DNP-enhanced SSNMR spectra acquired under purely
static conditions. DNP-enhanced 35Cl experiments are used to characterize APIs in bulk and dosage forms
with Cl contents as low as 0.45 wt%. These results are compared to DNP-enhanced 1H–13C CP/MAS
spectra of APIs in dosage forms, which are often hindered by interfering signals arising from the binders, fillers
and other excipient materials
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35Cl dynamic nuclear polarization solid-state NMR
of active pharmaceutical ingredients†
David A. Hirsh,a Aaron J. Rossini,*bc Lyndon Emsleyd and Robert W. Schurko*a
In this work, we show how to obtain eﬃcient dynamic nuclear polarization (DNP) enhanced 35Cl solid-state
NMR (SSNMR) spectra at 9.4 T and demonstrate how they can be used to characterize the molecular-level
structure of hydrochloride salts of active pharmaceutical ingredients (APIs) in both bulk and low wt%
API dosage forms. 35Cl SSNMR central-transition powder patterns of chloride ions are typically tens to
hundreds of kHz in breadth, and most cannot be excited uniformly with high-power rectangular pulses or
acquired under conditions of magic-angle spinning (MAS). Herein, we demonstrate the combination of
DNP and 1H–35Cl broadband adiabatic inversion cross polarization (BRAIN-CP) experiments for the
acquisition of high quality wideline spectra of APIs under static sample conditions, and obtain signals up to
50 times greater than in spectra acquired without the use of DNP at 100 K. We report a new protocol,
called spinning-on spinning-off (SOSO) acquisition, where MAS is applied during part of the polarization
delay to increase the DNP enhancements and then the MAS rotation is stopped so that a wideline
35Cl NMR powder pattern free from the effects of spinning sidebands can be acquired under static
conditions. This method provides an additional two-fold signal enhancement compared to DNP-enhanced
SSNMR spectra acquired under purely static conditions. DNP-enhanced 35Cl experiments are used to
characterize APIs in bulk and dosage forms with Cl contents as low as 0.45 wt%. These results are
compared to DNP-enhanced 1H–13C CP/MAS spectra of APIs in dosage forms, which are often hindered
by interfering signals arising from the binders, fillers and other excipient materials.
1. Introduction
The identification of solid forms of active pharmaceutical
ingredients (APIs) plays an important role in drug development,
both in the discovery of new forms and quality control.1–3 Each
polymorph, pseudopolymorph (such as a hydrate or solvate),
cocrystal, or salt of an API is uniquely patentable,4,5 and can have
substantially different physicochemical properties (stability,
solubility, bioavailability etc.).6–11 Undesired phases or impurities
in dosage forms are potentially dangerous or costly; hence, new and
innovative methods are needed for structurally characterizing APIs,
both in the bulk phase and especially within solid dosage forms.
Solid APIs are commonly characterized using X-ray diﬀrac-
tion (powder or single-crystal), 1H and 13C solid-state NMR
(SSNMR), thermogravimetric methods, and other spectroscopic
techniques.12–18 In many cases, these techniques provide
adequate characterization of the bulk forms of APIs; however, they
are often of limited use for dosage forms (especially those with low
weight percentages, wt%, of the API). In particular, both pXRD
patterns and 13C SSNMR spectra of dosage forms often display
interfering signals from the excipient (e.g., binding ingredients and
fillers), which obscure signals arising from the API.
Prior studies by our group19–21 and others22,23 have demon-
strated that 35Cl SSNMR is a valuable tool for characterizing the
bulk and dosage forms of APIs that have been synthesized as
HCl salts (excipients do not contain chloride ions, so there are
no interfering signals in 35Cl SSNMR spectra of dosage forms).
Since 35Cl is a quadrupolar nucleus (I = 3/2), its spectra are
influenced by a combination of anisotropic chemical shift and
quadrupolar interactions. The latter are particularly sensitive to
small structural differences in the local Cl anion environments
arising from variations in local hydrogen bonding.19,20,24–27
As a result, each solid phase of an API produces a distinct
35Cl SSNMR spectral fingerprint. Given the importance of
identifying low concentrations of API phases within dosage
forms (including impurities), it is crucial to improve the lower
detection limit (LDL) of 35Cl SSNMR experiments.
Our research group has developed pulse sequences that
enable the rapid acquisition of broad 35Cl SSNMR patterns
(hundreds of kHz or more) with high S/N, even at moderate
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field strengths (e.g., 9.4 T). Unlike older methods,28–30 these pulse
sequences rely on phase-modulated frequency-swept WURST
(wideband uniform-rate smooth truncation) pulses31,32 for broad-
band excitation and polarization transfer. The WURST-CPMG
(WCPMG)33,34 and broadband adiabatic inversion cross-polarization
(BRAIN-CP)35 pulse sequences are used for direct (35Cl) and indirect
(1H–35Cl) broadband excitation of 35Cl SSNMR spectra, respectively.
The BRAIN-CP-WCPMG sequence (BCP for short) uses BRAIN-CP
to transfer spin polarization from abundant nuclides (e.g., 1H)
to dilute nuclides (e.g., 35Cl), and a subsequent WURST-CPMG
pulse and windowed acquisition train for further signal enhance-
ment (Fig. S1, ESI†).
Over the past few years, high-field dynamic nuclear polar-
ization (DNP) has become a prominent method for achieving
high gains in S/N for SSNMR experiments.36–39 Recent develop-
ments in DNP NMR instrumentation (e.g., high-frequency
gyrotrons,40,41 low-temperature MAS probes42,43), optimized
radical polarizing agents,44–48 and the availability of commer-
cial DNP NMR spectrometers49,50 have enabled signal increases
in excess of 300, representing potential time savings by a factor
of 90 000. DNP has enabled SSNMR experiments that were
previously considered challenging/impossible, allowing the
detailed the study of materials that were previously inaccessible
to SSNMR.51–60 Most materials are prepared for DNP experi-
ments by using a simple incipient wetness impregnation pro-
cedure to coat the surface of the particles, or fill the porous
volume with a radical polarizing agent solution.47,61 Saturation
of the EPR transitions of the radicals with microwaves results in
enhanced polarization of the nuclei (most often protons) that
are in close proximity to the polarizing agents.46 In the case of
micro-particulate organic solids (e.g., APIs), DNP-enhanced
polarization can be relayed from the surface of the particles
into the interiors of the solids by 1H–1H spin diffusion without
perturbing their macroscopic structure.62,63 With this techni-
que, DNP-enhanced solid-state NMR can be applied to organic
solids,63–66 pure APIs,63,66–69 and low API wt% dosage forms.69
These developments have enabled natural isotopic abundance
13C–13C, 1H–15N and 13C–15N correlation SSNMR experiments,
which would be challenging or impossible without DNP.
To date, most DNP SSNMR studies have been limited to the
characterization of nuclei with fairly narrow powder patterns
(i.e., breadths on the order of tens of kHz or less). These reports
include the spectral acquisition of a variety of spin-1/2 nuclei as
well as quadrupolar nuclei in highly symmetric environments
(e.g., 2H, 14N overtone, 17O, 27Al, and 51V).55,56,64,66,70–75 However,
the enhancements afforded by DNP also make it an attractive
technique for the acquisition of NMR spectra of broader patterns
(e.g., 35Cl SSNMR) due to their inherently low S/N that largely
results from the distribution of NMR signal across a wide
frequency range. During the final preparation of the manu-
script describing our work, Kobayashi et al. published one
such example, in a report on DNP-enhanced ultra-wideline
195Pt SSNMR.76 One factor that hinders the acquisition of
DNP-enhanced wideline spectra from stationary samples is that
moderate- and fast-magic angle spinning (MAS) results in sub-
stantially higher DNP and sensitivity enhancements.47,50,77–79
MAS rates of ca. 6 to 40 kHz provide DNP enhancements (e) that
are ca. 3 to 5 times higher than those obtained from static (i.e.,
stationary sample) experiments.47,50,77,78 Unfortunately, MAS
experiments are not generally useful for patterns with breadths
on the order of 100 kHz or more, especially for quadrupolar
nuclides. First, MAS only results in partial averaging of the
effects of the second-order quadrupolar interaction, and second,
even very fast MAS may not result in the separation of the
spinning sidebands from the isotropic centerband.80 Matters
are further complicated by the effects of first-order quadrupolar
interactions and/or large chemical shift anisotropies. In many
cases, MAS spectra of broad patterns are distorted and have low
S/N, which prevents the accurate determination of quadrupolar
and chemical shift tensor parameters.
Herein, we show that DNP can be used to enhance S/N in
static wideline 35Cl SSNMR patterns of APIs acquired with BCP
methods. We detail a new protocol, called spinning-on spinning-
oﬀ (SOSO) acquisition, for enhancing the DNP polarization under
MAS and subsequently acquiring a wideline 35Cl pattern under
static conditions. These techniques result in DNP enhancements
in 35Cl SSNMR spectra of up to a factor of 110 at 100 K and
B0 = 9.4 T. We demonstrate the application of
35Cl DNP SSNMR
for the characterization of APIs in their bulk forms, as well as in
dosage forms with Cl contents of as low as 0.45 wt%. The
application of these techniques for polymorph diﬀerentiation,
impurity identification, and the discovery of new solid phases
are also demonstrated.
2. Methods
2.1 Sample preparation
Bulk samples of histidine hydrochloride monohydrate (hist),
ambroxol hydrochloride (ambr), isoxsuprine hydrochloride (isox),
diphenhydramine hydrochloride (diph), and cetirizine dihydro-
chloride (ceti), with purities ranging between 98 and 99 wt%, were
purchased from Sigma-Aldrich Canada, Ltd and used without
further purification (Fig. 1). A 10 mg tablet of isoxsuprine and a
25 mg tablet of Life Brand diphenhydramine obtained at local
pharmacies were used as the dosage forms of isox and diph,
respectively. The weight percentages of chlorine in the bulk and
dosage samples are tabulated in the ESI† (Table S2). To prepare
the samples for DNP SSNMR experiments, the bulk powders
were ground by hand for several minutes in a mortar and pestle
to reduce particle sizes, while the dosage form tablets were only
lightly crushed to break the tablets into a fine powder. The
samples were then impregnated52,61 with ca. 15 mL of 15 mM
TEKpol in 1,1,2,2-tetrachloroethane (TCE)47 (hist, ambr, isox) or
1,3-dibromobutane (DBB) (ceti, diph) and packed into 3.2 mm
sapphire rotors.
2.2 VT pXRD
Variable-temperature powder X-ray diﬀraction (pXRD) experi-
ments were conducted using the APEX III software suite and a
Bruker Photon 100 CMOS diﬀractometer with a graphite mono-
chromator with CuKa (l = 1.5406 Å). Samples were ground,
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packed into glass capillary tubes, and then cooled with a stream
of cold N2 from an Oxford cryostream attached to the diﬀracto-
meter. pXRD patterns were acquired for all of the samples
and the identities of the samples with known crystal struc-
tures were confirmed by comparison to simulated patterns
(Fig. S13, ESI†).81–84
2.3 NMR
13C and 35Cl SSNMR DNP experiments were conducted on a
9.4 T (400 MHz)/263 GHz Bruker Avance III solid-state DNP
NMR spectrometer50 using a 3.2 mm HXY probe configured for
1H–13C–35Cl experiments located at the DOE Ames Laboratory.
Carbon and chlorine chemical shifts were referenced to TMS at
0 ppm, using the unified scale in the IUPAC standard.85
Preliminary DNP NMR experiments were conducted at the EPFL
(Lausanne) on a Bruker Avance I solid-state DNP NMR spectro-
meter equipped with a 3.2 mm HXY probe configured for
1H–13C–35Cl.
The full experimental parameters used for the 13C and 35Cl
experiments are given in the ESI† (Tables S3–S6). NMR-13C: all
1H–13C CP/MAS experiments used a CP contact time of 2 ms,
and a constant 13C spin lock rf field of ca. 74 kHz. An MAS
frequency of 8 kHz (or 9 kHz for isox) was used. The 1H spin
lock amplitude was linearly ramped86–88 from ca. 75 kHz to
83 kHz. Proton decoupling was applied for each acquisition
using an rf field of 100 kHz and the SPINAL-64 pulse
sequence.89 NMR-35Cl: 1H–35Cl CP-CPMG and CP-echo spectra
of hist were acquired using conventional rectangular pulses
with ca. 70 kHz rf on both channels. The 1H–35Cl BRAIN-CP-
WURST-CPMG (BCP) pulse sequence35 was used to acquire the
spectra of all of the other samples. The sweep direction of the
WURST pulse applied during the BCP contact period can result
in lopsided powder patterns; to minimize these effects on the
35Cl powder patterns of isox and diph, two sub-spectra were
acquired with opposite sweep directions for the BCP contact
pulses. These sub-spectra were then co-added together to form
the final spectrum (Fig. S11, ESI†). With the exception of the
spectra of hist, all of the 35Cl spectra were acquired using
WURST-CPMG (WCPMG) refocusing pulses.33,34 To process
these spectra, the echoes in each FID were co-added to form
a single echo, which was then Fourier transformed and magni-
tude processed.
Because of the breadth of the 35Cl powder pattern of ceti
(vide infra), its 1H–35Cl BCP spectrum was acquired using
frequency-stepped acquisition.28,29,90 Four pieces were acquired
with the transmitter frequencies separated by 50 kHz increments.
These pieces were then co-added together to produce the final
spectrum.
The dipolar hetero-nuclear multiple-quantum correlation
rotatory-resonance recoupling (D-HMQC-R3) pulse sequence
91,92
was used to obtain a 2D dipolar 13C–35Cl correlation spectrum
in the hist sample. See Table S4 for the experimental para-
meters (ESI†).
2.4 Software
All spectra were processed using the TopSpin 3.2 software package.
Analytical simulations of the processed 35Cl SSNMR spectra
(Fig. S5–S9, ESI†) were generated using the Solid Lineshape
Analysis module (v. 2.2.4) within TopSpin. The resulting quadru-
polar and chemical shift parameters are listed in Table S7 (ESI†).
Simulated 35Cl MAS NMR spectra were obtained using the simula-
tion program for solid-state NMR spectroscopy (SIMPSON).93,94
3. Results and discussion
3.1 Histidine HCl
Histidine HCl (hist) is an excellent setup standard for DNP
experiments due to its long T1(
1H), which is ca. 284 s at 100 K.
Slow longitudinal relaxation is advantageous for remote DNP,
as it allows for increased 1H polarization buildup and greater
DNP enhancements.47 The 1H–13C CP/MAS NMR spectra of hist
obtained with and without microwaves are shown in Fig. 2a. The
corresponding 13C DNP enhancement (eCP(
13C) = 260) is the highest
measured for all of the compounds in this study. All 13C signals
from histidine are easily resolved and differentiated from the broad
1,1,2,2-tetrachloroethane (TCE) solvent peak at ca. 75 ppm.
Fig. 1 Molecular structures of APIs.
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The 1H–35Cl CP-CPMG NMR spectra of hist acquired with
and without DNP are shown in Fig. 2b. Even under completely
static sample conditions, a large DNP enhancement is observed
when the microwaves are turned on (eCP(
35Cl) = 50) (Fig. 2b).
However, when the sample is rotated during part of the 30 s
recycle/polarization delay, an additional 2.2-fold signal gain
over the static DNP experiment is observed (Fig. 2b). We call
this technique spinning-on spinning-off (SOSO). To acquire
the spectrum with SOSO, we manually controlled the sample
spinning at ca. 200 to 2000 Hz during the recycle delay and
stopped the sample spinning several seconds before collecting
a spectrum under static conditions (see Fig. S1 for a schematic
diagram of the pulse sequence timings, ESI†). This procedure
was repeated for each of the 4 to 8 scans in the experiment.
SOSO allows for a larger 1H polarization build-up due to improved
DNP while the sample is spinning and acquisition of a distortion-
free wideline spectrum under static conditions. The improved
DNP enhancement with spinning is consistent with previous
results that show increased DNP enhancements in 1H–13C
CP/MAS NMR spectra with increasing sample spinning speeds
up to ca. 10–15 kHz.47,50,77,78
In order to examine the eﬀects of slow MAS on DNP
eﬃciency (without the application of SOSO), a 35Cl SSNMR
spectrum was acquired with uninterrupted slow MAS at 250 Hz
and the CP-echo pulse sequence (Fig. 3a). Slow MAS yields a
central transition powder pattern that is very similar in appear-
ance to that obtained from a corresponding experiment on a static
sample (Fig. 3a and Fig. S2, ESI†). The signal in the spectrum
acquired with continuous slow MAS is ca. 3.1 times greater than
that acquired under static conditions (Fig. 3a). Thus, the DNP
enhancement under continuous MAS is slightly greater than that
obtained with SOSO (2.2 times, vide supra). The 35Cl DNP
enhancements in these spectra are lower than the enhancements
seen in the 13C NMR spectra, due in part to the slower MAS
frequencies used in both the SOSO and slow MAS 35Cl SSNMR
experiments.
Since hist has a small quadrupolar coupling constant, a
high-quality DNP enhanced CP-echo spectrum was also acquired
at a faster MAS frequency of 8 kHz (Fig. S3, ESI†), resulting
in a powder pattern free of overlapping spinning sidebands.
Fig. 2 13C and 35Cl SSNMR spectra of finely ground hist impregnated with
a 15 mM TEKPol/TCE solution acquired at 100 K and B0 = 9.4 T. (a)
1H–13C
CP/MAS spectra acquired with and without microwaves. The top inset
shows the two 13C spectra scaled to the samemaximum intensity. Asterisks
denote spinning sidebands. (b) 1H–35Cl CP-CPMG spectra acquired with
microwaves and rotation during part of the recycle delay period (SOSO
conditions, red), with microwaves and a stationary sample (blue), and a
stationary sample without microwaves (black). The inset shows a vertical
expansion of the 35Cl SSNMR spectra.
Fig. 3 (a) DNP-enhanced 35Cl SSNMR spectra of finely ground hist impregnated with a 15 mM TEKPol/TCE solution acquired with the CP-echo pulse
sequence under continuous slow MAS (nrot = 250 Hz) (red) and with the sample stationary at all times (blue). (b) 2D 13C–35Cl D-HMQC-R3 correlation
spectrum of hist acquired under MAS (nrot = 8 kHz) with a projection of the 2D data along the direct dimension axis and the 35Cl CPMAS-echo spectrum
shown along the indirect dimension axis.
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The DNP enhancement of this MAS spectrum (eCP(
35Cl) = 230)
is comparable to the enhancements seen in the 13C NMR
spectra (eCP(
13C) = 260, vide supra). While slow or moderate
MAS experiments may be useful for acquiring spectra of narrow
central transition patterns that can be partially averaged
(i.e., static pattern breadths o50 kHz, Fig. S3, ESI†), overlap
of the MAS powder patterns with spinning sidebands is proble-
matic for spectra with broader central transition patterns. Such
overlap yields spectra without clearly defined discontinuities,
which are diﬃcult to analyze (Fig. S4, ESI† and vide infra).
Given that the 35Cl SSNMR spectra of anionic chlorides in
hydrochloride salts of APIs typically have powder patterns with
breadths spanning 100–300 kHz at moderate field strengths,19–21
MAS 35Cl experiments with spinning rates between 5 and
15 kHz are not suitable for the characterization of most APIs.
Furthermore, the polarization transfer from 1H to quadrupolar
nuclei is often challenging to optimize and inefficient under
MAS conditions.95
All of the 35Cl SSNMR spectra of hist can be simulated with
the same quadrupolar tensor parameters: CQ = 1.8(1) MHz,
ZQ = 0.72(2), diso = 16(5) ppm (spectral simulations of these and
all other 35Cl powder patterns in this work can be found in the
ESI:† Fig. S5–S9 and Table S7). While these parameters agree with
those reported in a recent study by Pandey et al. (CQ = 1.8 MHz
and ZQ = 0.66),
22 they do not match those reported by Bryce et al.
for the room temperature spectrum of hist (CQ = 4.59 MHz,
ZQ = 0.46, diso = 93 ppm).
24 It is possible that the study by Bryce
et al. involved a different polymorph of hist.
DNP enhancement also provides access to two-dimensional
experiments that would otherwise be challenging or impossi-
ble. One such example is a 2D heteronuclear dipolar correlation
spectrum of proximate 13C and 35Cl nuclei. As a proof of
concept, we obtained a 13C–35Cl dipolar heteronuclear multiple-
quantum correlation spectrum (Fig. 3b) with rotatory-resonance
recoupling (D-HMQC-R3).91,92 This 2D spectrum shows correla-
tions between the 13C and 35Cl nuclei that are close to each
other. Such results may provide valuable distance constraints
on the structure of the molecule that may be useful for NMR
crystallography.96 With DNP at higher magnetic fields and/or
with faster sample spinning rates, it should be possible to
acquire 13C–35Cl correlation spectra for APIs with larger values
of CQ. 2D
13C–35Cl correlation NMR spectra could enable over-
lapping 35Cl powder patterns in APIs with multiple 35Cl sites to
be resolved by correlation to high resolution 13C resonances.
3.2 Ambroxol HCl
Ambroxol HCl (ambr) is an API that is used to treat a myriad of
respiratory diseases by clearing mucus from the respiratory tract.
It is sold under a variety of trade names, including Mucosolvan,
Mucobrox, Mucol, Lasolvan, Mucoangin, Surbronc, Ambolar,
and Lysopain. A substantial DNP-enhancement (eCP(
13C) = 92)
was measured for the 1H–13C CP/MAS NMR spectra of ambr
(Fig. 4a). The decreased enhancement relative to hist could
result from less favorable relaxation characteristics; the T1(
1H)
of ambr at 100 K (ca. 30 s) is far less than that of hist (ca. 284 s),
which limits the DNP enhancements of ambr.62,63
As with hist, DNP provides a considerable signal enhance-
ment (eCP(
35Cl) = 15) in the 1H–35Cl BCP NMR spectra acquired
under static conditions (Fig. 4b). If the SOSO procedure is used
(i.e., where the sample is spun slowly during most of the recycle
delay and then is stationary during the pulse and acquisition
periods), the DNP enhancement is further increased by a factor
2 and eCP(
35Cl) = 30 is observed (Fig. 4b). The combination of
DNP and BCP produces a high S/N spectrum, spanning roughly
200 kHz, (ca. 10 times broader than that of hist).
Given the breadth of the 35Cl powder pattern of ambr at
9.4 T, it is not possible to use conventional MAS (i.e., constant
spinning throughout the experiment). At the spinning speeds
typically used for DNP-enhanced 13C NMR experiments (i.e.,
between 8 and 15 kHz), the presence of spinning sidebands
distorts the 35Cl pattern and makes analysis of the powder
pattern challenging (Fig. S4, ESI†). These issues result because
(i) slower MAS rates do not average the eﬀects of the second-order
quadrupolar interaction, leading to patterns withmany overlapping
sidebands that are diﬃcult to simulate, and (ii) spinning speeds
exceeding 40 to 50 kHz are necessary to separate the spinning
sidebands from the isotropic centerband for typical values of 35Cl
CQ at 9.4 T (or hundreds of kHz for other quadrupolar nuclides).
80
Fig. 4 13C and 35Cl SSNMR spectra of finely ground ambr impregnated
with 15 mM TEKPol/TCE solution acquired at 100 K and B0 = 9.4 T.
(a) 1H–13C CP/MAS spectra acquired with and without microwaves to
drive DNP. The top inset shows the two 13C spectra scaled to the same
maximum intensity. The asterisks denote spinning sidebands. (b) 1H–35Cl
BCP spectra acquired with microwaves and slow MAS rotation during most
of recycle delay period (SOSO condition, red), with microwaves and with
the sample stationary at all times (blue), and with the sample stationary
without microwaves (black).
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However, DNP MAS probes with faster spinning rates have
recently become available,79 and may enable acquisition of
spectra exhibiting undistorted isotropic centerbands for 35Cl sites
with larger values of CQ.
There is a slight distortion in the low-frequency shoulder
(at ca. 70 kHz) of the pattern acquired with the SOSO method.
This distortion may arise from an improperly refocused CPMG
echo train, which results from the sample not coming to a com-
plete stop after spinning during the recycle delay – even very
slow spinning can be disastrous for these experiments (Fig. S10,
ESI†). The starting and stopping of the sample spinning was
performed manually for this preliminary set of experiments. In
the future, these issues could be addressed with the addition of
specialized hardware to precisely control the spinning rate and
stop/start timings of the sample. Alternatively, longer recycle
delays could be employed, at the expense of a slight reduction
in sensitivity.
3.3 Isoxsuprine HCl
The API isoxsuprine HCl (isox), commonly sold as Duvadilan,
is a vasodilator used for both human and equine treatments.
We have previously characterized isox in its bulk and dosage
forms using 35Cl static NMR experiments without DNP.21 The
1H–13C CP/MAS NMR spectra of both the bulk and dosage
forms of isox (Fig. 5a and b, respectively) can be acquired in
only a few minutes with DNP (eCP(
13C) = 86 and 32, respectively).
The DNP enhancement of the signal from the API in the dosage
form is much less than that from the bulk form of the API
(a trend that continues with the other dosage form samples in this
study, vide infra). Such lower DNP enhancements for dosage forms
are likely due to: (i) differences in the particle sizes of the API in
the bulk and dosage forms, (ii) the distribution of the radical
solution in the sample, (iii) the presence of the excipient, or
(iv) some combination of these factors. First, there are likely
differences in the size of the API particles in the bulk and
dosage forms due to the processing the API undergoes during
tablet manufacturing. Second, the radical solution may be
adsorbed preferentially by excipients during the impregnation
step, or, if most of the API particles were coated with an excipient
(e.g., a polymer) during production of the dosage form, the
radical solution may not penetrate the excipient.69 Finally, the
API particles may be coated with an excipient phase having an
intrinsically short T1(
1H), a very high concentration of protons, or
unfavorable dielectric properties that reduce local microwave
fields. All of these effects would reduce DNP enhancements of
the 1H nuclei at the surface of the API particles and subsequently
inside the cores of the API particles. DNP enhancements could
probably be further improved on a case by case basis by optimiz-
ing the solvent used for impregnation (including investigating
the use of fully- and partially-deuterated solvents), the concen-
tration of radical in the solution, and the amount of radical
solution used for the impregnation step.62,63
Another complication is that the DNP enhancements of
signals arising from the API, solvent, and excipient molecules
are not the same, as was observed in a prior study of several
cetirizine dosage forms using DNP-enhanced 13C SSNMR.69
Fig. 5 SSNMR spectra of the bulk and dosage forms of isox impregnated with a 15 mM TEKPol/TCE solution acquired at 100 K and B0 = 9.4 T. The left
column has 1H–13C CP/MAS spectra of (a) the bulk API and (b) the dosage samples acquired with microwaves on and off. The bottom inset shows the full
spectra of the dosage form without vertical clipping. The right column has 1H–35Cl BCP spectra of (c) the bulk API with and without microwaves and
(d) the bulk API and dosage samples with DNP enhancement. The lineshapes in (c) are lopsided to the high frequency side because only one sweep
direction of the BCP contact pulse was used (see Fig. S10 for more details, ESI†).
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In the case of isox (Fig. 5b, inset), the strongest signal is observed
for a feature at 74.8(2) ppm, which corresponds to the solvent,
TCE (eCP(
13C) = 104). This intense feature dominates the spec-
trum of the dosage form and obscures several peaks from the
API. The DNP enhancement of the unobscured API signal (e.g.,
peaks at ca. 110–135 ppm), eCP(
13C) = 32, is less than that of
the solvent. Finally, there are features that correspond to
various types of excipient molecules, including polysaccharides
(20–40 ppm), synthetic polymers (60–75 ppm) and stearates
(100–110 ppm),69,97,98 which have enhancements ranging from
12 to 50. Overlapping signals from the API and excipient make
it challenging to determine the phase of an API in 13C NMR
spectra even without the use of DNP;21 however, the differences
in the DNP-enhancement such as those observed in the spectra
of isox can further complicate the analysis. While the signal
from the solvent can be decreased by adding a spin-echo to the
pulse sequence99 doing so only marginally improves the resolu-
tion of the features from isox (Fig. S14, ESI†).
35Cl SSNMR can selectively probe the API in the dosage form
without interfering signals from the excipients, since chloride
ions are only found in the API and the 35Cl signal from covalently-
bound chlorines would be extremely broad and of too low
intensity to be detected.100–102 A comparison of the DNP-
enhanced 1H–35Cl BCP NMR spectra of bulk and dosage forms
of isox is shown in Fig. 5d. The DNP enhancement observed for
isox under static conditions (Fig. 5c, eCP(
35Cl) = 12) is compar-
able to that of ambr (cf. Fig. 4b). Both the 35Cl SSNMR spectra of
the bulk and dosage forms of isox are consistent with spectra
acquired without DNP19 (see Fig. S7 for the spectral simulation
and associated quadrupolar parameters, ESI†). The fact that
the powder pattern of the tablet matches that of the bulk
compound confirms that both samples contain the same poly-
morph of isox. There are additional features in the centers of
both patterns (with centers of gravity at ca. 0 ppm). While the
origin of this feature is still under study, it may result from Cl
anions coordinated to H2O (e.g., as a result of disproportionation
of the HCl salt), or some other chemical or physical alteration of
the sample (see VT-pXRD patterns in Fig. S12, ESI†).
A primary advantage of DNP experiments is that dosage
forms of APIs can be studied even if the wt% of the API is very
low, as is the case for isox (4.95 wt% API, 0.52 wt% Cl). Here, the
combined acquisition time of the 35Cl spectra of the pure and
dosage forms of isox with DNP was just over 10 hours, roughly
half the experiment time necessary to acquire a comparable set
of spectra at room temperature.21 Such time savings are critical
in the high-throughput screening of dosage forms with low wt%
APIs. Given the long acquisition times required to obtain suﬃ-
cient 35Cl signal without microwaves, we have not attempted to
acquire these spectra, and cannot report an enhancement in the
spectrum of dosage isox (or the other dosage forms, vide infra).
SOSO experiments were not conducted on isox because of its
short T1(
1H) of 15 s. The short T1(
1H) limits the amount of time
available for 1H polarization build up before the polarization is
lost to longitudinal relaxation. Roughly 25 s were required to
start the sample spinning and completely stop rotation, which
was not fast enough to fit within the optimal polarization
time (20 s) for the experiments with isox. Of course, a longer
polarization time could be applied to perform the SOSO
method; however, the gains from increased DNP enhancement
would be partially oﬀset from reduced sensitivity arising from use
of a recycle delay longer than 1.3  T1. As with ambr (vide supra),
the 35Cl powder pattern is too broad for conventional MAS to
be used.
3.4 Diphenhydramine HCl
Diphenhydramine HCl (diph) is a widely used antihistamine,
most commonly sold under the trade name Benadryl. The
1H–13C CP/MAS NMR spectra of both bulk diph (Fig. 6a) and the
dosage form (Fig. 6b) show fair DNP enhancement (eCP(
13C) = 25
and 16, respectively) and can be acquired in 2 minutes or less.
The most intense feature in both of these spectra is a broad
feature at ca. 50(2) ppm, which corresponds to the solvent,
1,3-dibromobutane (DBB). DBB was used for these experiments
because diph was found to be soluble in TCE. Distinct features
corresponding to the API (e.g., at 128(1) ppm) can be distin-
guished from those of the solvent and excipient in the spectrum
of the dosage form (Fig. 6b).
The DNP enhancement observed in these spectra is not
as high as those observed in the spectra of the other samples
(Fig. 2, 4, and 5). One contributing factor is that diph, like isox,
has a relatively short T1(
1H) (ca. 18 s), which limits the build-up
of enhanced polarization in the microcrystalline solid. The
choice of solvent for the radical also plays an important role,
as prior studies have reported decreased enhancements when
using DBB rather than TCE, however, DBB was required for
solubility reasons.47,48,103 Another disadvantage of the use of
DBB is that it produces a broad solvent peak in the 13C SSNMR
spectra, which can obscure features from the API and excipient
and make confirmation of the phase and purity even more
diﬃcult. Clearly, the identification of other compatible solvents
is an important future step for the further optimization of DNP
experiments on APIs.
Unlike the 13C spectra, the 1H–35Cl BCP NMR spectra of diph
(Fig. 6d) are free from signal interference from the excipient
and solvent. The breadths of the powder patterns and locations
of the discontinuities are identical, which confirm that the same
phase of diph is present in both the bulk and dosage forms.
These features are also consistent with previous work done at
room temperature.21 As with the spectra of isox, there is an
additional low-intensity feature at ca. 4(2) ppm that may result
from disproportionation of the API. It is difficult to measure the
DNP enhancement of these spectra due to the low S/N in the
spectrum acquired without microwaves (Fig. 6c). The estimated
minimum value of eCP(
35Cl) = 7 was obtained by comparing the
spectra after applying a Fourier transform directly to the CPMG
echo train (see Fig. S15, ESI†).
Prior 35Cl SSNMR studies of this compound have relied on
direct excitation experiments (e.g., WCPMG)21 because attempts
to use CP at room temperature were unsuccessful due to poor
CP eﬃciency. While CP experiments are still a challenge at low
temperature, they are possible with the use of DNP. Unfortunately,
the variation of CP eﬃciency with temperature when using the
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BCP pulse sequence is not well understood. DNP experiments,
such as those reported here, could provide opportunities for
further understanding the CP dynamics, and lead to improve-
ments to the BCP sequence and related experiments under DNP
conditions.
3.5 Cetirizine HCl
SSNMR is extremely useful for the study of APIs that form solid
amorphous phases.104,105 One such API is cetirizine dihydro-
chloride (ceti), an antihistamine that is commonly sold under
the trade names Zyrtec and Reactine.
The 1H–13C CP/MAS NMR spectra of the bulk and dosage
samples of ceti are shown in Fig. 7a and b, respectively, and are
consistent with previous studies of this compound using DNP-
enhanced 13C SSNMR.69 Several distinct features from the API are
apparent in the spectrum of bulk ceti (e.g., peaks at 60–70 ppm and
130–200 ppm). However, only the strongest signal from the API (at
ca. 130 ppm) can be distinguished in the spectrum of the dosage
form due to interference from the excipients. In both spectra of ceti,
there is less interference from the solvent than was observed in the
spectra of diph (cf. Fig. 6a and b), because the DNP enhancement of
the solvent peak is not as large (e(DBB, ceti) = 24, e(DBB, diph) = 50).
The enhancement of the solvent varies from sample to sample,
which may depend on the types and concentrations of different
excipients, the quality of the glass formation when the radical-
containing solution freezes, the amount of dissolved O2(g), the
dielectric properties of the sample that affect the microwave
field,106 or the other factors discussed above.
The enhancement observed in the spectrum of bulk ceti
(eCP(
13C) = 20) is close to what was previously reported for this
compound (eCP(
13C) = 31).69 However, for ceti in the dosage
form we measured eCP(
13C) = 8, which is lower than the 55-fold
enhancement previously reported. We attribute these decreased
enhancements to the use of DBB as the radical solvent. In the
previous DNP SSNMR study, ceti was found to be sparingly
soluble in TCE.69 We chose to use DBB (in which ceti is
insoluble) to maximize the amount of solid sample in the rotor
and to better maintain the structure of the API in the dosage
form. Given that the discrepancy in enhancements is particularly
apparent in the spectra of the dosage form, it is possible that
DBB does not penetrate the excipients as well as TCE. Further
optimization of the sample preparation could likely yield improved
enhancements.
Ceti is a dihydrochloride, and its 35Cl SSNMR spectra should
show two distinct 35Cl patterns corresponding to structurally
unique Cl anion sites. With the use of DNP, it is possible to
identify two overlapping powder patterns in the 35Cl spectrum
of the bulk form in just 5 minutes (eCP(
35Cl) = 5.8, Fig. 7c). Due
to hardware limitations, it is challenging to uniformly excite the
entire breadth of the two 35Cl patterns of ceti, even with BCP.
As such, we used frequency-stepped acquisition28,29 and com-
bined 4 sub-spectra at evenly spaced transmitter frequencies to
obtain the full pattern (which is ca. 250 kHz broad, Fig. S9, ESI†).
The two overlapping 35Cl powder patterns with distinct quadru-
polar parameters can be readily distinguished using analytical
simulations. Nonetheless, the most important discontinuities in
Fig. 6 13C and 35Cl SSNMR spectra of the bulk and dosage forms of diph impregnated with a 15 mM TEKPol/1,3-dibromobutane solution acquired at
100 K and B0 = 9.4 T. The left column has
1H–13C CP/MAS spectra of (a) the bulk API and (b) the dosage samples acquired with microwaves on and off.
Asterisks denote spinning sidebands. The right column has 1H–35Cl BCP spectra of (c) the bulk API with and without microwaves and (d) the bulk API and
dosage samples with DNP enhancement. The lineshape in (c) is lopsided to the high frequency side because only one sweep direction of the BCP contact
pulse was used (see Fig. S10 for more details, ESI†).
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the two patterns can be observed in the central sub-spectrum
(as in Fig. 7c and d).
Acquiring a 35Cl SSNMR spectrum of the dosage form with
similar signal-to-noise ratio takes more than 11 hours, due
to the extremely low wt% Cl in this sample (5.78 wt% API,
0.45 wt% Cl), which is the lowest discussed herein. Comparison
of the 35Cl spectra of the bulk and dosage forms (Fig. 7d) shows
that the dosage form likely contains two 35Cl environments that are
similar to those of the bulk form. However, the poorer resolution of
the discontinuities in the 35Cl spectrum of the dosage form (most
evident at the center of the pattern) is consistent with the lower
crystallinity of the API within the formulation. This API was
previously confirmed to exist as an amorphous form in all
formulations using DNP-enhanced 13C and 15N SSNMR in the
previous study.69
4. Conclusions
We have demonstrated the acquisition of high-quality static
wideline 35Cl SSNMR spectra of APIs using the 1H–35Cl BRAIN-
CP-WURST-CPMG pulse sequence under DNP conditions. DNP
has been observed to enhance the 35Cl SSNMR signal by as much
as 110 times for stationary samples. This enhancement is achieved
by using a new spinning-on spinning-off (SOSO) protocol, in which
the sample is spun during the recycle delay and halted shortly
before the pulse/acquisition periods. The use of SOSO results in a
build-up in 1H polarization under MAS conditions and allows for
the acquisition of a wideline 35Cl spectrum free of spinning
sidebands under static conditions. This method provides an
additional two-fold signal enhancement over the spectra acquired
with DNP under purely static conditions. The use of DNP
dramatically decreases the lower detection limit for 35Cl SSNMR
spectra of dosage forms; we report successful characterization
of APIs in bulk and dosage forms with Cl contents as low as
0.45 wt%. These 35Cl NMR spectra are particularly useful for the
identification of the API within the dosage form because they
are not affected by interfering signals from excipient molecules
in the pill. In this respect, the DNP-enhanced 1H–13C CP/MAS
spectra of the dosage forms are limited, despite having higher
signal enhancements than the corresponding 35Cl NMR spectra.
For all of the systems in this study, we observed lower DNP
enhancements in the spectra of the dosage forms than in those
of the bulk API, possibly due to the presence of excipients that
reduce DNP efficiency via a number of different mechanisms, or
due to differences in the particle size of the API in the bulk and
dosage samples. These techniques show potential for investi-
gating the sizes of micro- and nanoparticles of APIs in dosage
forms.69 Finally, we have demonstrated the use of DNP signal
enhancement for the acquisition of a two-dimensional 13C–35Cl
correlation NMR spectrum of histidine HCl monohydrate. The
increasing availability of DNP MAS probes with faster spinning
rates79 will allow for the acquisition of 1D and 2D 35Cl MAS NMR
spectra of most chloride salts of APIs and other organic mole-
cules, with CQ values as high as 7 to 8 MHz at 9.4 T.
The techniques we have reported in this study will help
expand the use of DNP to the study of other wideline and ultra-
wideline (breadths 4 250 kHz) powder patterns. While the
Fig. 7 13C and 35Cl SSNMR spectra of the bulk and dosage forms of ceti impregnated with 15 mM TEKPol/1,3-dibromobutane solution acquired at 100 K
and B0 = 9.4 T. The left column has
1H–13C CP/MAS spectra of (a) the bulk API and (b) the dosage samples acquired with and without microwaves.
Asterisks denote spinning sidebands. The right column shows the 1H–35Cl BCP spectra of (c) the bulk API with and without microwaves and (d) the bulk
API and dosage samples with DNP enhancement.
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spectra reported herein are dominated by the second-order
quadrupolar interaction, the techniques described should would
work equally well for patterns that are broadened by the first-
order quadrupolar interaction, chemical shift anisotropy, or
combinations thereof. These developments make DNP useful
for the study of a wide range of materials whose NMR spectra
suﬀer from inherently low S/N largely due to the wide breadth of
the signal.
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